<DOC>
	<DOC>NCT00532961</DOC>
	<brief_summary>Phase IV, randomized, double-masked, parallel-group clinical trial comparing the ocular tolerability and steroid-induced intraocular pressure (IOP) effects of Zylet wth that of TobraDex in healthy volunteers, when either product was administered QID (at approximately 4-hour intervals) for 28 days.</brief_summary>
	<brief_title>Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<criteria>in good general health based on investigator judgment able and willing to follow instructions, provide informed consent, make the required study visits, and use an electronic patient diary during the study possessing a best corrected visual acuity of at least 20/40 in each eye for females, using reliable contraception and a negative urine pregnancy test prior to study entry contact lenses worn within 30 days prior to enrollment or during study period known hypersensitivity to study medication or any component presence of significant ocular or systemic disease that might interfere with the interpretation of the results a need for administration of chronic topical ocular or systemic medications of any kind during the study. participation in an opthalmic drug or device research study within 30 days prior to entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>